2007 Flavodoxin-like
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Mixed metal/non-metal compounds | 74 | 25.1 | 2.95× | q < 0.0001 | |
| Organic oxygen compounds | 335 | 238.0 | 1.41× | q < 0.0001 | |
| Homogeneous non-metal compounds | 321 | 257.2 | 1.25× | q < 0.0001 | |
| Organic acids and derivatives | 221 | 184.9 | 1.20× | q = 8.4e-3 | |
| Organosulfur compounds | 25 | 24.6 | 1.02× | q = 0.95 | |
| Nucleosides, nucleotides, and analogues | 304 | 330.3 | 0.92× | q = 0.13 | |
| Homogeneous metal compounds | 496 | 586.6 | 0.85× | q < 0.0001 | |
| Benzenoids | 72 | 87.4 | 0.82× | q = 0.14 | |
| Organic nitrogen compounds | 29 | 38.1 | 0.76× | q = 0.19 | |
| Organoheterocyclic compounds | 114 | 183.9 | 0.62× | q < 0.0001 | |
| Lipids and lipid-like molecules | 60 | 133.1 | 0.45× | q < 0.0001 | |
| Phenylpropanoids and polyketides | 11 | 24.9 | 0.44× | q = 5.9e-3 | |
| Hydrocarbons | 0 | 8.4 | 0 | q = 8.9e-4 | |
| Organophosphorus compounds | 1 | 0.4 | 2.47× | not tested | |
| Miscellaneous inorganic compounds | 1 | 0.9 | 1.12× | not tested | |
| Organometallic compounds | 1 | 1.7 | 0.59× | not tested | |
| Organohalogen compounds | 1 | 3.4 | 0.29× | not tested | |
| Alkaloids and derivatives | 1 | 4.1 | 0.24× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00141 | NAG | N-Acetylglucosamine | 868 |
| DB03247 | FMN | Flavin mononucleotide | 538 |
| DB03147 | FAD | Flavin adenine dinucleotide | 256 |
| DB14128 | NAD | Nadide | 227 |
| DB00142 | GLU | Glutamic acid | 180 |
| DB02338 | NDP | NADPH | 174 |
| DB01992 | COA | Coenzyme A | 147 |
| DB03461 | NAP | Nicotinamide adenine dinucleotide phosphate | 135 |
| DB00171 | ATP | ATP | 127 |
| DB02517 | DGL | D-Glutamic Acid | 108 |
| DB02379 | BGC | Beta-D-Glucose | 97 |
| DB03581 | G6Q | Glucose-6-Phosphate | 95 |
| DB16833 | ADP | Adenosine disphosphate | 86 |
| DB00157 | NAI | NADH | 83 |
| DB09459 | TLA | L-tartaric acid | 81 |
| DB00130 | GLN | L-Glutamine | 78 |
| DB02548 | S6P | D-glucitol 6-phosphate | 73 |
| DB04162 | INI | 5-Nitro-6-ribityl-amino-2,4(1H,3H)-pyrimidinedione | 70 |
| DB18267 | HEM | Ferroheme | 66 |
| DB02659 | CHD | Cholic Acid | 61 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| NAG | 2-acetamido-2-deoxy-beta-D-glucopyranose | 1,390 |
| MGmetal | MAGNESIUM ION | 1,139 |
| CL | CHLORIDE ION | 1,132 |
| CAmetal | CALCIUM ION | 830 |
| SF4 | IRON/SULFUR CLUSTER | 778 |
| ZNmetal | ZINC ION | 682 |
| FMN | FLAVIN MONONUCLEOTIDE | 561 |
| ICS | iron-sulfur-molybdenum cluster with interstitial carbon | 462 |
| HCA | 3-HYDROXY-3-CARBOXY-ADIPIC ACID | 458 |
| NAmetal | SODIUM ION | 404 |
| FEmetal | FE (III) ION | 391 |
| CLF | FE(8)-S(7) CLUSTER | 382 |
| MNmetal | MANGANESE (II) ION | 329 |
| FAD | FLAVIN-ADENINE DINUCLEOTIDE | 278 |
| NDP | NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE | 262 |
| NAD | NICOTINAMIDE-ADENINE-DINUCLEOTIDE | 258 |
| B12 | COBALAMIN | 205 |
| BEF | BERYLLIUM TRIFLUORIDE ION | 158 |
| Kmetal | POTASSIUM ION | 152 |
| COA | COENZYME A | 148 |